Completed PHASE2/PHASE3 INTERVENTIONAL 1-arm NCT01100099

HLA-DQ2-gliadin Tetramer for Diagnosis of Celiac Disease

Sponsor: Oslo University Hospital

Updated 5 times since 2017 Last updated: Sep 18, 2012 Started: Sep 30, 2006 Primary completion: Dec 31, 2009 Completion: Sep 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01100099, this PHASE2/PHASE3 trial focuses on Celiac Disease and Gluten and remains completed. Sponsored by Oslo University Hospital, it has been updated 5 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Oslo University Hospital
South-Eastern Norway Regional Health Authority
University of Oslo

Data source: Oslo University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Oslo, Norway